Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma

Hatsuyo Takaoka, Hideki Terai, Katsura Emoto, Lisa Shigematsu, Fumimaro Ito, Ayaka Saito, Masahiko Okada, Keiko Ohgino, Shinnosuke Ikemura, Hiroyuki Yasuda, Ichiro Nakachi, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima

研究成果: Article査読

抄録

We report the first case of a patient with non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE) who achieved disease-and treatment-free survival for nearly 10 years. A 50-year-old man was diagnosed with NSCLC with MPE and underwent chemotherapy and salvage thoracic surgery. The patient received chemotherapy with cisplatin, pemetrexed, and bevacizumab, and a partial response was achieved. After informed consent was obtained from the patient, right middle lobectomy was performed to achieve local tumor control. Postoperative adjuvant chemotherapy with pemetrexed and bevacizumab was discontinued after almost 1 year of chemotherapy due to side effects such as diarrhea and muscle weakness. The patient has survived without recurrence of lung cancer for more than 11 years after being diagnosed and nearly 10 years after discontinuing chemotherapy.

本文言語English
ページ(範囲)981-989
ページ数9
ジャーナルOncoTargets and Therapy
15
DOI
出版ステータスPublished - 2022

ASJC Scopus subject areas

  • 腫瘍学
  • 薬理学(医学)

フィンガープリント

「Long-Term Treatment-Free Survival After Multimodal Therapy in a Patient with Stage IV Lung Adenocarcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル